Electroporation improves the efficacy of DNA vaccines in large animals

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3399-3408

  Babiuk, Shawn ^a   Baca Estrada, Maria E ^b   Foldvari, Marianna ^a   Storms, Michael ^c   Rabussay, Deitmar ^c   Widera, Georg ^c   Babiuk, Lorne A ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Inovio Biomedical Corporation   (United States)

Author keywords

In vivo electroporation; Intramuscular DNA vaccination; Multiple antigens

Indexed keywords

DNA VACCINE; GLYCOPROTEIN D; HEPATITIS B SURFACE ANTIGEN; PLASMID DNA; PLASMID VECTOR; PRIMER DNA; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOVINE HERPES VIRUS; CONTROLLED STUDY; DRUG EFFICACY; ELECTRODE; ELECTROPORATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNITY; IMMUNOSTIMULATION; MALE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIRUS GENE;

ANIMALS; ANTIBODIES, VIRAL; ELECTROPORATION; FEMALE; GENES, REPORTER; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HERPESVIRUS 1, BOVINE; HUMANS; IMMUNOGLOBULIN G; LUCIFERASES; MALE; MICE; PLASMIDS; SPECIES SPECIFICITY; SUS SCROFA; VACCINES, DNA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0037056017     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00269-4     Document Type: Article

References (34)

1. van Drunen Littel-van den Hurk S., Gerdts V., Loehr B.I.et al. Recent advances in the use of DNA vaccines for the treatment of diseases of farmed animals. Adv. Drug Deliv. Rev. 43:2000;13-28.
2. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7213-7218.
3. Hoffman S.L., Sedegah M., Hedstrom R.C. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine. 12:1994;1529-1533.
4. Ulmer J.B., Montgomery D.L., Tang A.et al. DNA vaccines against tuberculosis. Nov. Found. Symp. 217:1998;239-246.
5. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
6. Lehmann-Grube F., Lohler J., Utermohlen O., Gegin C. Antiviral immune responses of lymphocytic choriomeningitis virus-infected mice lacking CD8+ T lymphocytes because of disruption of the beta 2-microglobulin gene. J. Virol. 67:1993;332-339.
7. MacGregor R.R., Boyer J.D., Ugen K.E.et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178:1998;92-100.
8. Turnes C.G., Aleixo J.A., Monteiro A.V., Dellagostin O.A. DNA inoculation with a plasmid vector carrying the faeG adhesin gene of Escherichia coli K88ab induced immune responses in mice and pigs. Vaccine. 17:1999;2089-2095.
9. Ugen K.E., Nyland S.B., Boyer J.D.et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16:1998;1818-1821.
10. Robinson H.L., Montefiori D.C., Johnson R.P.et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:1999;526-534.
11. Richmond J.F., Lu S., Santoro J.C.et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol. 72:1998;9092-9100.
12. Jones T.R., Narum D.L., Gozalo A.S.et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183:2001;303-312.
13. van Drunen Littel-van den H., Braun R.P., Lewis P.J.et al. Intradermal immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in cattle. J. Gen. Virol. 79:1998;831-839.
14. Kotsopoulou E., Kim V.N., Kingsman A.J., Kingsman S.M., Mitrophanous K.A. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74:2000;4839-4852.
15. Zucchelli S., Capone S., Fattori E.et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J. Virol. 74:2000;11598-11607.
16. Widera G., Austin M., Rabussay D.et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164:2000;4635-4640. [in process citation].
17. Glasspool-Malone J., Somiari S., Drabick J.J., Malone R.W. Efficient non-viral cutaneous transfection. Mol. Ther. 2:2000;140-146.
18. Heller R., Schultz J., Lucas M.L.et al. Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol. 20:2001;21-26.
19. Krieg A.M., Wu T., Weeratna R.et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12631-12636.
20. Uwiera R.R., Rankin R., Adams G.P.et al. Effects of intradermally administered plasmid deoxyribonucleic acid on ovine popliteal lymph node morphology. Anat. Rec. 262:2001;186-192.
21. Lewis P.J., van Drunen Littel-van den H., Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J. Virol. 73:1999;10214-10223.
22. van Drunen Littel-van den Hurk S., van Donkersgoed J., Kowalski J.et al. A sub-unit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine. 12:1994;1295-1302.
23. Hofmann G.A., Dev S.B., Dimmer S., Nanda G.S. Electroporation therapy: a new approach for the treatment of head and neck cancer. IEEE Trans. Biomed. Eng. 46:1999;752-759.
24. Nanda G.S., Sun F.X., Hofmann G.A., Hoffman R.M., Dev S.B. Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res. 18:1998;999-1004.
25. Weeratna R., Brazolot Millan C.L., Krieg A.M., Davis H.L. Reduction of antigen expression from DNA vaccines by co-administered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 8:1998;351-356.
26. van Drunen Littel-van den Hurk S., Gifford G.A., Babiuk L.A. Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins. Vaccine. 8:1990;358-368.
27. Tikoo S.K., Campos M., Popowych Y.I., van Drunen Littel-van den Hurk S., Babiuk L.A. Lymphocyte proliferative responses to recombinant bovine herpesvirus type-1 (BHV-1) glycoprotein gD (gIV) in immune cattle: identification of a T-cell epitope. Viral Immunol. 8:1995;19-25.
28. Baca-Estrada M.E., Snider M., Tikoo S.K., Harland R., Babiuk L.A., van Drunen Littel-van den Hurk S. Immunogenicity of bovine herpesvirus-1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol. 9:1996;11-22.
29. Benne C.A., Harmsen M., van der Graaff W., Verheul A.F., Snippe H., Kraaijeveld C.A. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A sub-unit vaccine using various adjuvants. Vaccine. 15:1997;1039-1044.
30. Martinez X., Brandt C., Saddallah F.et al. DNA immunization circumvents deficient induction of T-helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8726-8731.
31. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:1998;3949-3957.
32. Braun R., Babiuk L.A., van Drunen Littel-van den H. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J. Gen. Virol. 79:1998;2965-2970.
33. Rabussay DP, Nanda GS, Goldfard MP. Enhancing the effectiveness of drug-based cancer therapy by electroporation (electropermeabilization). J Tech Cancer Res Treat 2002, in press.
34. Rodriguez-Cuevas S., Barroso-Bravo S., Almanza-Estrada J., Cristobal-Martinez L., Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch. Med. Res. 32(4):2001;273-276.